processes, which are highly useful for assessing the efficacy of (novel) therapeutic 41 compounds in a time-and labor-efficient manner. 
Introduction

43
Aspergillus fumigatus is an opportunistic pathogen which is ubiquitous in the lesions, but also for the quantification of imaging-derived biomarkers such as the lung 57 tissue volume. However, besides obtaining insight into structural changes occurring in 58 the lung upon infection, it is also crucial to obtain information on fungal growth in order 59 to fully comprehend all aspects of developing disease and treatment response. As an 60 alternative for standard invasive techniques such as colony-forming unit (CFU) 61 counting to assess infection, there has been great interest in using non-invasive 62 imaging techniques to quantify the fungal load.
63
Bioluminescence imaging (BLI) is an optical technique based on the detection of 64 photons, which are generated by an enzymatic reaction upon luciferin substrate 65 administration (9). To apply this imaging modality in the infectious diseases field, 66 pathogens have to be genetically modified to express the luciferase enzyme. As only infections. These difficulties were overcome by using a codon-optimized firefly 80 luciferase, which enabled to study disseminated candidiasis and revealed an 81 unexpected persistence of C. albicans in the gall bladder under antifungal therapy (26).
82
The firefly luciferase has also been successfully used to monitor invasive aspergillosis 83 caused by A. fumigatus (10). In a first approach of using the bioluminescent strain, it 84 was possible to visualize the early stages of disease in a cortisone-induced mouse 
Materials and Methods
106
Fungal strain 107 The bioluminescent Aspergillus fumigatus strain 2/7/1 was used (28). The strain was was diluted to a final concentration of 2.5 x 10 7 spores/ml or 1.0 x 10 7 spores/ml. counted on day 0 (n = 3) and day 4 (n = 3) using the Advia 2120i hematology system 123 (Siemens Healthcare GmbH, Erlangen, Germany).
124
On day 0, the animals were anesthetized with 1.5-2% isoflurane (Abbott Laboratories, fumigatus spores, as previously described (8). Directly after instillation, the mice were 128 positioned upright until normal breathing was resumed. In this manuscript, all times are 129 stated relative to the day of inoculation, which will be referred to as day 0. 
138
The disease course was monitored by acquiring MRI scans before infection (baseline)
139
and on day 1, 2, 3, 4, 5 and 14 PI. In addition, in vivo BLI scans were acquired on day 140 3, 5 and 9 PI. Non-treated animals (n = 10 for the high inoculum group; n = 5 for the 141 low inoculum group) did not receive voriconazole nor grape fruit juice. For these mice,
142
daily MRI and in vivo BLI scans were acquired until day 4 PI for the high inoculum 143 group and until day 7 PI for the low inoculum group.
144
During image acquisition, the mice were anesthetized with 1.5-2% isoflurane in 100% µl D-luciferin (7.5 mg) by inserting a catheter (22-gauge) into the trachea, after which 157 the tissue was isolated and immediately placed in the flow chamber to perform a scan.
158
The BLI images were processed using the Living Image software (version 4.5.4, Perkin
159
Elmer, Hopkinton, USA). A circular region of interest (ROI) covering the complete lung 160 area was used to measure the total photon flux. x 128 matrix, 273 µm isotropic resolution and a total acquisition time of 18 minutes (8).
171
The acquired MR images were analyzed using an in-house written Mevislab module In this study, mice were rendered leucopenic by two injections of cyclophosphamide. seemed to decrease by day 5 and returned to background levels by day 9 ( figure 4D ).
262
The quantified values were an order of magnitude lower on day 3 compared to the 
337
We also investigated the feasibility to non-invasively monitor the effects of voriconazole the development of the observed inflammatory response (33) . 
